Skip to main content
Premium Trial:

Request an Annual Quote

MedDay Acquires Health Assets of Profilomic

NEW YORK (GenomeWeb) – MedDay Pharmaceuticals announced today that it has acquired the health division of Profilomic, a spinout of France's Alternative Energies and Atomic Energy Commission (CEA).

Under the terms of the transaction, Paris-based MedDay has picked up all of Profilomic's health-related assets including lab equipment, a database, and a team of scientists focused on metabolomics and lipidomics. MedDay said that the deal is expected to strengthen its existing cerebrospinal fluid-based metabolomics research platform — called SPECMET — which was developed in collaboration with the CEA.

Financial terms were not disclosed.

"Tackling unmet medical need in central nervous system disorders by acting on brain metabolism is the driving force behind MedDay," MedDay CEO Frédéric Sedel said in a statement. "With the acquisition of Profilomic, we have significantly expanded our research capabilities and are excited to expand our pipeline."